SCHEMBL6473082

SCHEMBL6473082

CCCCCCC(=O)CNCc1cccc(-c2ccc(C=C(CC(=O)OCC)C(=O)OC)cc2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 5/20 0.38
PPARA Q07869 3/20 0.38
FAAH O00519 2/20 0.38
PPARG P37231 1/20 0.38
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TRPV1 Q8NER1 1/20 0.34
ICMT O60725 1/20 0.34
PPID Q08752 1/20 0.34
HDAC3 O15379 3/20 0.33
HDAC4 P56524 3/20 0.33
HDAC1 Q13547 3/20 0.33
HDAC7 Q8WUI4 3/20 0.33
HDAC2 Q92769 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6473073 1.00 EPHX2 (0.38) EPHX2PPARAFAAHPPARGKDM4E
SCHEMBL6182804 0.83 TDP1 (0.40) EPHX2PPARAFAAHPPARGLMNA
SCHEMBL6473080 0.83 AOC3 (0.41)
SCHEMBL6531479 0.83 PPID (0.37) EPHX2PPID
SCHEMBL6531486 0.83 PPID (0.37) EPHX2PPID
SCHEMBL6473177 0.82 PRMT6 (0.42) EPHX2PPID
SCHEMBL6473169 0.82 PRMT6 (0.42) EPHX2PPID
SCHEMBL6473530 0.79 MMEL1 (0.41) EPHX2PPARAFAAHPPARGHDAC1
SCHEMBL6473078 0.77 AOC3 (0.41)
SCHEMBL6531485 0.77 PPID (0.36) EPHX2PPID

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD EPHX2 1174/4885PPARA 2/4885FAAH 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.